http://www.the-infoshop.com/pharmaceutical.shtml Pharmaceutical Market Research Reports Global Information, Inc. (C) 2008 Global Information, Inc. 2009-11-06 daily en Pharmaceutical Companies 2009-11-04 Business Insights http://www.the-infoshop.com/study/rb103176-cmo-market.html Falling productivity and patent expiries are placing increasing pressure on pharmaceutical companies to reduce fix costs including large manufacturing facilities. Sponsors are turning to CMOs in search of time and cost savings and as a way to flexibly manage outsourced manufacturing. Meanwhile the threat of overcapacity combined with inevitable program cancellations following mega-mergers resist the market. en 2009-11-04 Business Insights http://www.the-infoshop.com/study/rb103178-optimizing-lifecycle.html The need to derive the maximum commercial mileage from all components of a drug company' s portfolio is clearly evident in an era of falling returns on investment and higher capital costs. This report investigates three goals in optimizing product potential- expanding the drug' s patent protected lifespan, accessing broader patient populations and launching line-extensions via fixed dose combinations. en OTC Drug 2009-11-03 James Dudley International, Ltd. http://www.the-infoshop.com/study/jdi83657-otc-distribution-in-euro.html OTC Distribution in Europe 2010 edition is an in-depth strategic 18 country study. It defines and explores the main themes of change running through the European region and shows how they will influence the channel strategies for manufacturers' of non-prescription and OTC self-medication as well associated consumer healthcare products. en Neurodegenerative Disease 2009-11-02 Jain Pharmabiotech http://www.the-infoshop.com/study/jai70919-neuroprotection.html This report describes the role of neuroprotection in acute disorders such as stroke and injuries of the nervous system as well as in chronic diseases such as neurodegenerative disorders because many of the underlying mechanisms of damage to neural tissues are similar in all these conditions and several products are used in more than one disorder. en Drug Delivery System 2009-11-02 Jain Pharmabiotech http://www.the-infoshop.com/study/jai70921-transdermal.html This report deals with transdermal drug delivery - an approach used to deliver drugs through the skin for therapeutic use as an alternative to oral,intravascular, subcutaneous and transmucosal routes. Various transdermal drug delivery technologies are described including the use of suitable formulations, carriers and penetration enhancers. en 2009-11-02 Jain Pharmabiotech http://www.the-infoshop.com/study/jai70923-pain-therape.html This report describes the latest concepts of pathomechanisms of pain as a basis for management and development of new pharmacotherapies for pain. Major segments of the pain market are arthritis, neuropathic pain and cancer pain. Because pain is a subjective sensation, it is difficult to evaluate objectively in clinical trials. Various tools for pain measurement are described, including brain imaging. en 2009-11-02 Jain Pharmabiotech http://www.the-infoshop.com/study/jai70925-nitric-oxide.html This report describes the latest concepts of the role of nitric oxide (NO) in health and disease as a basis for therapeutics and development of new drugs. Major segments of the market for nitric oxide-based drugs are described as well as the companies involved in developing them. en Neurodegenerative Disease 2009-11-02 Jain Pharmabiotech http://www.the-infoshop.com/study/jai70927-alzheimer.html Alzheimer' s disease remains a challenge in management. With nearly 8 million sufferers from this condition in the seven major markets of the world and anticipated increases in the future. Considerable research is in progress to understand the pathomechanism of the disease and find a cure. en Drug Delivery System 2009-11-02 Jain Pharmabiotech http://www.the-infoshop.com/study/jai70928-drug-deli.html Drug delivery remains a challenge in management of cancer. Approximately 12.5 million new cases of cancer are being diagnosed worldwide each year and considerable research is in progress for drug discovery for cancer. Cancer drug delivery is no longer simply wrapping up cancer drugs in a new formulations for different routes of delivery. The focus is on targeted cancer therapy. The newer approaches to cancer treatment not only supplement the conventional chemotherapy and radiotherapy but also prevent damage to normal tissues and prevent drug resistance. en Neurodegenerative Disease 2009-11-02 Jain Pharmabiotech http://www.the-infoshop.com/study/jai70934-central-nervous.html The delivery of drugs to central nervous system (CNS) is a challenge in the treatment of neurological disorders. Drugs may be administered directly into the CNS or administered systematically (e.g., by intravenous injection) for targeted action in the CNS. The major challenge to CNS drug delivery is the blood-brain barrier (BBB), which limits the access of drugs to the brain substance. en Drug Delivery System 2009-11-02 Jain Pharmabiotech http://www.the-infoshop.com/study/jai70936-cardiovascular.html Drug delivery to the cardiovascular system is different from delivery to other systems because of the anatomy and physiology of the vascular system; it supplies blood and nutrients to all organs of the body. Drugs can be introduced into the vascular system for systemic effects or targeted to an organ via the regional blood supply. In addition to the usual formulations of drugs such as controlled release, devices are used as well. This report starts with an introduction to molecular cardiology and discusses its relationship to biotechnology and drug delivery systems. en Infection Disease 2009-11-01 Markets and Markets http://www.the-infoshop.com/study/mama102658-h1n1vaccin.html H1N1 Influenza A (2009) is the first pandemic influenza of 21st century affecting more than more than four lac people in more than 180 countries across the globe in 2009. The flu broke in Mexico in the month of March and then affected U.S. and after that it spread across the globe. H1N1 (2009) influenza have a mutation of pig, bird and humans which has made it more dangerous and fatal compared to previous occurrence of H1N1 (1918). en Infection Disease 2009-10-26 Frost & Sullivan http://www.the-infoshop.com/study/fs102574-hk-fung-infection.html This research service aims to provide an update on the epidemiology of systemic fungal infection, current diagnostic and treatment practices, as well as market landscape in terms of major participants and future trends. It covers the systemic fungal infection therapeutics market in Hong Kong. en Infection Disease 2009-10-23 Frost & Sullivan http://www.the-infoshop.com/study/fs102575-ph-fung-infection.html This research service aims to provide an update on the epidemiology of systemic fungal infection, current diagnostic and treatment practices, as well as market landscape in terms of major participants and future trends. It covers the systemic fungal infection therapeutics market in the Philippines. en Infection Disease 2009-10-23 Frost & Sullivan http://www.the-infoshop.com/study/fs102576-kr-fung-infection.html This research service aims to provide an update on the epidemiology of systemic fungal infection, current diagnostic and treatment practices, as well as market landscape in terms of major participants and future trends. It covers the systemic fungal infection therapeutics market in South Korea. en Infection Disease 2009-10-22 Frost & Sullivan http://www.the-infoshop.com/study/fs102422-sys-fung-infection.html This research service aims to provide an update on the epidemiology of systemic fungal infection, current diagnostic and treatment practices, as well as market landscape in terms of major participants and future trends. It covers the systemic fungal infection therapeutics market in Malaysia. en Pharmaceutical Companies 2009-10-21 BCC Research http://www.the-infoshop.com/study/bc102343-contract-pharma.html This report explores present and future strategies within the contract manufacturing, research, and packaging pharmaceuticals industry. The needs, services offered, criteria for selection, and the advantages of outsourcing are discussed. The study also includes the need for project management, market forecasts and a discussion of the market leaders in the industry. Regulatory requirements and current state of the outsourcing market in the pharmaceuticals and biotechnology industry are also portrayed in this report. en Pharmaceutical Companies 2009-10-21 Cutting Edge Information http://www.the-infoshop.com/study/cei102381-phar-merg-acqui.html Pharmaceutical Mergers and Acquisitions guides you to build an M&A plan that focuses on key goals, avoids costly mistakes, and realizes deal potential as quickly as possible. CEI designed this study to identify the primary drivers of M&A activity. Through the input of pharma industry leaders, our study provides solutions to the greatest M&A pitfalls and gives clear, detailed insight of trends in pharmaceutical deals. The result: a roadmap to the M&A landscape. en 2009-10-21 Datamonitor http://www.the-infoshop.com/study/dc102404-colorectal-cancer.html CRC incidence will be over 490,000 cases by 2018 in the seven major markets. This large patient base will translate into a high commercial potential for the development of novel, more effective therapies. Currently, there are 77 agents in development for CRC, 4 of which are in late-phase development. Collectively, they are forecast to achieve sales of $1,398m by 2018. en Diabetes 2009-10-20 Datamonitor http://www.the-infoshop.com/study/dc102408-antidiabetic-australia.html Datamonitor expects the Australian antidiabetics market to reach $416m by 2018. The growth will be driven by the launch of new drug classes, notably the incretin mimetics, and large growth in patient numbers. Although strongest growth is expected in the non-insulin market, the insulin market will continue to dominate, generating revenues of $224m 10 years from now. en Cancer 2009-10-19 Frost & Sullivan http://www.the-infoshop.com/study/fs102289-glob-skin-cancer.html This research service analyses the global skin cancer therapeutics market. It analyses market drivers, restraints and challenges faced by industry participants. Revenue forecasts and pipeline analysis has been discussed. It also provides strategic recommendations. en Mental Disease 2009-10-16 Urch Publishing, Ltd. http://www.the-infoshop.com/study/ur102220-addiction-disorder.html The substance dependence field is transforming into a high-growth market opportunity. Supported by the success of Pfizer' s recently launched Chantix/Champix, which is on track for blockbuster status in the smoking cessation sector, pharmacotherapies in development for alcohol, narcotic, and nicotine dependencies are poised to radically change the addiction treatment landscape in this difficult-to-treat patient population. The report estimates that the current market for addiction disorders is valued at US$3.2 billion and this is forecast to increase 19% to US$3.8 billion by 2016. en Generic Drugs 2009-10-15 Espicom Business Intelligence http://www.the-infoshop.com/study/es102251-biosimilars.html The future of the pharmaceutical industry lies with biotechnology. Biotech drugs account for around 10-15% of the current pharmaceutical market, and the sector is outperforming the market as a whole in terms of growth. en Infection Disease 2009-10-14 France Innovation Scientifique et Transfert (FIST SA) http://www.the-infoshop.com/study/fist102157-hiv-therapy-patent.html The Human Immunodeficiency Virus (HIV) is a double-stranded RNA virus from the Retroviridae family. Discovered in 1983, HIV is responsible for the Acquired Immune Deficiency Syndrome (AIDS). Its mechanisms of action and transmission were described in the years following its discovery, and the first treatment, called azidothymidine or azidovudine, was marketed in 1987 as a monotherapy. en Infection Disease 2009-10-14 France Innovation Scientifique et Transfert (FIST SA) http://www.the-infoshop.com/study/fist102159-malaria-patent.html Malaria, along with HIV and Tuberculosis, is one of the three most common infectious diseases in the world. It has infected human beings for over 50,000 years and may have been a human pathogen throughout the entire history of our species. An estimated 300 million people suffer from this disease and more than one million die each year. en Drug Discovery 2009-10-12 Datamonitor http://www.the-infoshop.com/study/dc102412-rheumatoid-arthritis.html Drugs with new mechanisms, in particular Pfizer' s oral JAK inhibitor CP-690,550 and Chugai/Roche' s Actemra (tocilizumab), will launch for rheumatoid arthritis and should offer advantages over current therapies, but do not come without some safety signals. Late-stage pipeline launches will be a major contributor to market growth from $7.4 billion in 2008 to $11.5 billion in 2018. en Mental Disease 2009-10-08 Datamonitor http://www.the-infoshop.com/study/dc102087-novel-mechanism.html With current blockbuster brands facing generic competition, Datamonitor forecasts the antidepressant market to decline at a compound annual growth rate of -2.0% (20082018). However, an antidepressant with a novel mechanism of action has huge commercial potential and the most promising candidate to date is Servier and Novartis' s melatonin agonist and serotonin antagonist Valdoxan (agomelatine). en Neurodegenerative Disease 2009-10-08 Datamonitor http://www.the-infoshop.com/study/dc102088-parkinsons-disease.html The Parkinson' s disease market is approaching maturity, with the threat of generic incursion evident in each drug class. Although growth will be stifled by generic launches, relatively successful lifecycle management strategies and new product launches see the Parkinson' s disease market grow at a compound annual growth rate (CAGR) of 2.6% over the next 10 years (20082018). en Cancer 2009-10-08 Datamonitor http://www.the-infoshop.com/study/dc102089-acute-leukemias.html The drug therapy of acute myeloid leukemia (AML) and adult acute lymphoblastic leukemia (ALL) is largely based on chemotherapy regimens that have changed little in the past few decades. Patient outcomes for both diseases remain poor, particularly for elderly and high-risk patients. As the limits of cytotoxic chemotherapy are being reached, an unmet need remains for novel, improved therapies. en Neurodegenerative Disease 2009-10-08 Datamonitor http://www.the-infoshop.com/study/dc102090-anticonvulsants.html In 2008, seven major market sales of anticonvulsants reached $13.6 billion, making it one of the largest therapeutic drug classes in the Pharmaceutical sector. However, generic incursion of second generation anticonvulsants will continue to increase the barrier to entry for prospective players, although viable commercial opportunities exist to optimize returns from this lucrative drug class market en Generic Drugs 2009-10-06 Espicom Business Intelligence http://www.the-infoshop.com/study/es101214-glob-generics.html The operating environment for generic companies is changing rapidly as the industry matures and growth focuses on new market opportunities. en Neurodegenerative Disease 2009-10-06 Insight Pharma Reports http://www.the-infoshop.com/study/cd101944-immuno-vaccine.html This report: Covers a wide range of conditions for which immunotherapies may be effective, including Alzheimer' s disease, addiction, other neurological indications, cardiovascular diseases, hematological disorders, ophthalmic diseases, bone metabolism disorders, type 2 diabetes, among others Reviews emerging immunotherapies and vaccines for these indications as well as business considerations for companies active in these markets Includes expert interviews Applications of immunotherapies and vaccines for prevention and treatment of infectious diseases and cancer are well known. en 2009-10-05 BioPharm Reports (Technology and Markets Ltd) http://www.the-infoshop.com/study/bph102131-stroke.html This report presents the findings of a global survey on current treatments and prescribing practices for Ischaemic Stroke, Haemorrhagic Stroke and Transient Ischaemic Attack (TIA). These findings were made following the participation of more than 230 clinics worldwide, which provided detailed information on their treatment practices. en Pharmaceutical Companies 2009-10-02 Cutting Edge Information http://www.the-infoshop.com/study/cei101076-pharma-speaker.html The ever-present regulatory scrutiny that the life science industry currently faces has not overlooked speaker events. Soaring healthcare costs and worries about the influence of drug companies on prescribing behavior bring any intersection of the two communities under the harsh glare of inspection. For speaker programs, new regulation limits the measures the pharmaceutical company had at their disposal to entice physicians to attend. en Pharmaceutical Companies 2009-10-02 Datamonitor http://www.the-infoshop.com/study/dc101286-allergan-inc.html This analysis examines the historical and forecast performance for Allergan in the Rx pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information. en Pharmaceutical Companies 2009-10-02 Datamonitor http://www.the-infoshop.com/study/dc101287-chugai-pharma.html This analysis examines the historical and forecast performance for Chugai in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information. en Infection Disease 2009-10-02 Datamonitor http://www.the-infoshop.com/study/dc101288-hiv.html Three new partnerships are reshaping the competitive environment in HIV. Most notably, Tibotec/Johnson & Johnson is linking up with Gilead to combine their Phase III drug rilpivirine with Truvada to create a new gold standard fixed dose combination for treatment-naive patients. Addressing Atripla' s shortcomings, Datamonitor expects this product to dominate the market. en Drug Discovery 2009-10-02 Datamonitor http://www.the-infoshop.com/study/dc101289-orphan-drug.html With the pharmaceutical industry reducing its focus on the primary care blockbuster model, Big Pharma is now looking towards the development and commercialization of more niche, high value, often biologic therapies, for the treatment of smaller patient populations. en 2009-10-02 Datamonitor http://www.the-infoshop.com/study/dc101290-hormonal-contracept.html Since the 1960s, hormonal contraceptives have been widely used as effective birth control in the developed world. Although they are mainly used to prevent pregnancies, they can be used for treating other conditions such as acne, endometriosis, and polycystic ovarian syndrome. In 2008, the hormonal contraceptives market was worth $6.2 billion across the seven major pharmaceutical countries. en 2009-10-02 Datamonitor http://www.the-infoshop.com/study/dc101940-pharma101.html The life sciences industry is unique and complex. Without having the proper background, it can be difficult for IT vendors to enter this conservative market. Those willing to put in the extra effort to truly understand the pharmaceutical and biotechnology industries will realize there is considerable opportunity for technology. en Veterinary Medicine 2009-10-01 Kalorama Information http://www.the-infoshop.com/study/kl100084-veterinary-diagno.html Diagnostic tests are an essential tool for confirming the health status of animals. The global impact of diseases such as bovine spongiform encephalopathy, foot and mouth disease, and highly pathogenic avian influenza has revealed that diagnostic tests play a key role not only in facilitating safe trade but also in many other areas such as the early detection of new diseases and the control of exotic or enzootic animal diseases. en 2009-10-01 Global Industry Analysts, Inc. http://www.the-infoshop.com/study/go100761-health-spas.html The global outlook series on Health Spas provides a collection of statistical findings, market briefs, and concise summaries of research findings. Market discussions in the report are amply illustrated with 61 fact-rich market data tables, charts, and graphs. en 2009-10-01 Global Industry Analysts, Inc. http://www.the-infoshop.com/study/go100764-life-coaching.html The global outlook series on Life Coaching provides a collection of market briefs, and concise summaries of research findings. The report offers a bird' s eye view of the industry; highlights latest market trends, and demand drivers. Overview of the industry' s most noteworthy regional market, the US, is provided with unbiased research commentary to provide the reader a rudimentary understanding of the prevailing market climate. en Infection Disease 2009-10-01 Trimark Publications http://www.the-infoshop.com/study/tk100904-infec-diseas-drug.html According to the World Health Organization (WHO), six infectious diseases--pneumonia, tuberculosis, diarrheal diseases, malaria, measles and HIV/AIDS--account for half of all premature deaths worldwide, killing mostly children and young adults. en Pharmaceutical Companies 2009-10-01 CurrentPartnering, a division of Wildwood Ventures Limited http://www.the-infoshop.com/study/wild101043-drug-delivery-pharma.html The Drug Delivery Partnering Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the drug delivery partnering agreements entered into by the worlds leading healthcare companies. en 2009-10-01 Global Industry Analysts, Inc. http://www.the-infoshop.com/study/go101276-alternative-med.html The global outlook series on Alternative Medicine provides anecdotes, market briefs, and concise summaries of research findings. The report highlights the primary growth drivers, market challenges, and reviews global and regional trends across various segments. Market discussions in the report are amply illustrated with 33 fact-rich market data tables, charts, and graphs.Regional markets briefly abstracted include the United States, Canada, Japan, Europe, the United Kingdom, Denmark, China, India, Taiwan, and Australia. Also included is an indexed, easy-to-refer, fact-finder directory listing the addresses, and contact details of 463 companies worldwide. en 2009-10-01 Kalorama Information http://www.the-infoshop.com/study/kl101994-wellness-programs.html Utilization of wellness programs in the United States has experienced strong recent growth this is expected to continue through the forecast period. As more people participate in wellness programs, their usage of various health care products and services will be affected, as well the revenues of wellness program providers. This report looks at the emerging wellness industry and estimates the market for wellness related products and services. en Infection Disease 2009-10-01 Kalorama Information http://www.the-infoshop.com/study/kl101995-anti-infective.html The anti-infective market is at a critical juncture. For the past 60 years, antibiotic drugs have turned bacterial infections into treatable conditions rather than the life-threatening scourges they once were. But the effectiveness of many antibiotics is waning dramatically, as more and more types of bacteria become resistant to them. This Kalorama Information The World Market for Anti-Infectives considers the anti-infective drug market as it faces challenges with resistance and generic competition. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es13856-boehringer.html Pharmaceutical company intelligence reports from Espicom provide a full review of the company' s activities together with five-year sales forecasts for its key products. The company' s financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es13872-be-pharma.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es13896-ru-pharma.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es15383-il-pharma.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es15838_solvay.html Pharmaceutical company intelligence reports from Espicom provide a full review of the company' s activities together with five-year sales forecasts for its key products. The company' s financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es15978-nz-pharma.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es17860_recordati_pharma.html Pharmaceutical company intelligence reports from Espicom provide a full review of the company' s activities together with five-year sales forecasts for its key products. The company' s financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es18375_pharmaceutical.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. en Pharmaceutical Companies 2009-09-30 Espicom Business Intelligence http://www.the-infoshop.com/study/es19512_japan_pharma_company.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. en Pharmaceutical Companies 2009-09-30 Business Insights http://www.the-infoshop.com/study/rb100892-counterfeit-p-trade.html Parallel trade is a legitimate method of pharmaceutical import and export within the EU zone. Although previously recognized in North America as illegal, cross-border reimportation is now permitted following legislation allowing drugs to be imported into the US from Canada. en Infection Disease 2009-09-30 Mintel International Group Ltd, http://www.the-infoshop.com/study/mt101101-health-hygiene.html Qualitative research run by Mintel with Toluna shows that, although people claim not to have changed their hygiene habits in the wake of the swine flu publicity, they do appear to be more aware of germs. en 2009-09-30 Frost & Sullivan http://www.the-infoshop.com/study/fs101198-pharma-med-devi.html This research service provides a thorough analysis of various aspects of the healthcare industry in the Central and Eastern Europe (focusing on Poland, the Czech Republic, Slovakia, Hungary and Bulgaria). Originally, the research provides the insight of the impact of socio-economic and political factors on the development of the healthcare industry. en 2009-09-30 Frost & Sullivan http://www.the-infoshop.com/study/fs101201-pharma-med-devi.html This research service provides a thorough analysis of various aspects of the healthcare industry in Russia and some CIS countries (Ukraine, Kazakhstan, Belarus). Originally, the research provides the insight of the impact of socio-economic and political factors on the development of the healthcare industry. en OTC Drug 2009-09-30 Euromonitor International http://www.the-infoshop.com/study/eo102481-analgesics-finland.html This report presents Analgesics in Finland. en Regulation 2009-09-29 Business Insights http://www.the-infoshop.com/study/rb100891-middle-east-pharma.html The Middle East pharmaceutical market is diverse, with a significant presence of leading global players alongside domestic pharmaceutical companies such as Ibrahim, Bilim and Deva. en 2009-09-28 BCC Research http://www.the-infoshop.com/study/bc100798-gastro-pharma.html This report is designed to be a comprehensive business tool to provide an in-depth look at gastrointestinal disorders. The geographic scope of the report is global with a particular emphasis on the United States. Market data is global. The report provides an overview of the gastrointestinal system; gives a brief explanation of disorders of the gastrointestinal system; cites risk factors, where applicable; cites incidence and mortality; presents current pharmaceutical treatments, market size and market participants in both prescription and OTC arenas; and presents potential treatments in research and development, potential market size, and market participants. This report describes the industry in detail, its relationship to the healthcare industry, its participants, and its trends for the future. en 2009-09-25 Decision Resources, Inc. http://www.the-infoshop.com/study/dr100760-in-pharma-pricing.html Faced with a dramatic slowdown in sales in mature pharmaceutical markets, multinational pharmaceutical companies are looking to substantially increase their sales in India and other emerging markets. The Indian market is growing by more than 10% per year, but foreign companies will need to overcome signifi cant obstacles to succeed in a market currently dominated by domestic manufacturers. en Pharmaceutical Companies 2009-09-25 Espicom Business Intelligence http://www.the-infoshop.com/study/es100797-pharma-m-a.html Mergers and, more commonly, acquisitions have long been popular in the pharmaceutical industry. Whether it has been to support flagging drug pipelines, secure IP on promising drug candidates or to quickly access new markets, the industry has for many years been characterised by a vibrant M&A culture. The current recession has, therefore, had a significant impact on the industry' s players, and in more ways than might be immediately obvious. en 2009-09-25 Decision Resources, Inc. http://www.the-infoshop.com/study/dr100808-health-technology.html The use of health technology assessment (HTA) is growing steadily in Europe, and the U.S. government has recently announced $1.1 billion in funding for comparative effectiveness research (CER) as part of its planned overhaul of the U.S. healthcare system. Payers in all markets will increasingly compare new drugs with established therapies and offer the most favorable pricing and reimbursement terms only to drugs that are deemed innovative. en OTC Drug 2009-09-25 Euromonitor International http://www.the-infoshop.com/study/eo101146-sleeping-mexico.html This report presents Calming And Sleeping Products in Mexico. en Generic Drugs 2009-09-24 Markets and Markets http://www.the-infoshop.com/study/mama100546-biosimilars.html The impending expiry of several patented blockbuster biopharmaceuticals and the increasing demand from patients, insurers, and government agencies to reduce drug costs have created numerous opportunities in the global biosimilars market. The global biosimilars market is expected to be worth US$19.4 billion by 2014, growing at a CAGR of 89.1% from 2009 to 2014. The biosimilars market is segmented into peptides, recombinant glycosylated proteins, recombinant non-glycosylated proteins, and others. en 2009-09-24 Frost & Sullivan http://www.the-infoshop.com/study/fs100706-bw-pharma-ind.html This research service presents an in-depth analysis of the Botswana pharmaceutical industry. It provides a general insight into processes of regulations, medical insurance, healthcare procurement and financing. An analysis of key industry dynamics affecting each of pharmaceutical segments is presented, as well as industry sizes and growth rates over the period 2008-2015. In addition, a thorough competitor analysis for each industry was performed. en 2009-09-23 Decision Resources, Inc. http://www.the-infoshop.com/study/dr100642-sarcoidosis-treat.html I' d love there to be a better agent, says a thought leader on the current state of sarcoidosis treatment. Many sarcoidosis patients require little or no treatment, but patients with chronic disease need a therapy that is safer than the corticosteroids that have become the mainstay treatment for the disease. Because substantial market constraints have limited development in this therapeutic area, only a few novel agents are in the pipeline. However, opportunity remains for an agent that can address some of the unmet needs in this market. en Cancer 2009-09-22 Datamonitor http://www.the-infoshop.com/study/dc100878-cytotoxic-a-patent-cliff.html The cancer therapies market offers a high level of commercial reward to a handful of companies including Roche, Sanofi-Aventis, AstraZeneca, Novartis and Eli Lilly. Cancer therapy sales totaled over $38 billion in the seven major pharmaceutical markets in 2008, growing at a CAGR of 17.4% between 2005 and 2008. en Vaccines 2009-09-18 BCC Research http://www.the-infoshop.com/study/bc100147-dna-vaccine.html The study scope includes DNA vaccine products that are commercial or likely to be commercialized within the next 5 years. Both human and animal health markets are studied. DNA vaccine delivery technologies are also included. DNA vaccine candidates in clinical trials are examined by indication, and future market growth from 2009 through 2014 is estimated. en Drug Discovery 2009-09-18 Decision Resources, Inc. http://www.the-infoshop.com/study/dr100337-pharma-rd.html Can radical changes to the structures and strategies of pharmaceutical R&D operations - such as creating more entrepreneurial environments modeled upon biotech companies - increase their productivity? Many major companies are reorganizing the research branches of their businesses and fi nding creative ways to partner with biotech companies and with each other to access or acquire promising technologies and pipelines. Their goal is to reinvigorate R&D and combat the effects of patent expirations, generics competition, and other industry pressures. en 2009-09-18 Frost & Sullivan http://www.the-infoshop.com/study/fs100429-pharma-ingredi.html This study provides an overview of the global active pharmaceutical ingredients market. It is broadly divided into three chapters- API market analysis, therapeutic-area wise analysis and recommendations to market participants. en Neurodegenerative Disease 2009-09-18 Visiongain http://www.the-infoshop.com/study/kt102656-neurodegenerative.html Rising neurodegenerative disease prevalence and expanding patent populations - where are the best opportunities and how can you unlock these? Our new report - World Neurodegenerative Diseases Market 2009-2024 - explains. en OTC Drug 2009-09-17 Euromonitor International http://www.the-infoshop.com/study/eo100286-cn-otc-healthc.html OTC healthcare continued its healthy growth in 2008, mainly due to rising disposable income levels and growing health awareness among consumers. Robust economic development in China underpinned improving living standards, which enabled consumers to spend more on OTC healthcare. Meanwhile, consumers also became more educated about personal wellbeing via conventional mass media such as TV and newspapers as well as via emerging new media channels such as the internet. OTC healthcare manufacturers also played an important role in consumer education during the review period. Consequently, consumers gained more confidence in self-medication, leading to stronger sales of OTC healthcare. en Pharmaceutical Companies 2009-09-16 Datamonitor http://www.the-infoshop.com/study/dc100995-novo-nordisk.html This analysis examines the historical and forecast performance for Novo Nordisk in the Rx pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information. en Pharmaceutical Companies 2009-09-16 Datamonitor http://www.the-infoshop.com/study/dc100996-gilead-sciences.html This analysis examines the historical and forecast performance for Gilead in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information. en 2009-09-15 Decision Resources, Inc. http://www.the-infoshop.com/study/dr100333-biopharma-ind.html The biotechnology and pharmaceutical sectors as we know them will soon cease to exist. Companies in these sectors have come face-to-face with the harrowing ordeals of a global recession. Four stresses on the industry are rapidly depleting cash reserves, changing sources of growth, the specter of comparative effectiveness, and the threat posed by biosimilars. Staying alive in the short term and creating a more viable way of doing business are serious concerns. Many biotech companies have put themselves on ice with skeleton staffs in an attempt to ride out the recession, but they may never recover their scientifi c momentum. Mid-tier pharmaceutical companies are scrambling and fear for their independence. A new world order is on the horizon that will be a more unifi ed biopharmaceutical industry. This report addresses the issues underlying the evolving nature of the biotech and mid-tier pharmaceutical sectors and identifi es strategies and opportunities for moving forward. en 2009-09-15 Decision Resources, Inc. http://www.the-infoshop.com/study/dr100335-compani-diagno.html Some naysayers disagree, but we regard companion diagnostics as a win-win scenario for all stakeholders. Companion diagnostics combines drug and diagnostic test development. The potential for effi cient drug development is huge because companion diagnostics can be used to predict drug response and treatment effi cacy - therefore, companion diagnostics are also the perfect means to fulfi llment of the promise of personalized medicine. But the advantages of companion diagnostics are only one side of the equation: they are also seen as disruptors of the pharmaceutical market that could restrict the size of treatable populations. Bringing the differing viewpoints together to form a unifi ed idea of what companion diagnostics really mean to the industry is a challenge, but one that companies must heed because companion diagnostics are making their mark - like it or not. en Pharmaceutical Companies 2009-09-14 Datamonitor http://www.the-infoshop.com/study/dc101002-astrazeneca.html This analysis examines the historical and forecast performance for AstraZeneca in the Rx pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information. en Pharmaceutical Companies 2009-09-14 Datamonitor http://www.the-infoshop.com/study/dc101004-pharmavitae.html This analysis examines the historical and forecast performance for Abbott in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information. en Pharmaceutical Companies 2009-09-10 La Merie http://www.the-infoshop.com/study/lmer100177-egf-r-agonists.html The present Competitive Intelligence Report about EGF-R agonists and antagonists provides a competitor evaluation in the field of epidermal growth factor receptor (EGF-R; ErbB1) targeting molecules for wound healing or treatment of cancer as of September 2009. en Regulation 2009-09-10 Decision Resources, Inc. http://www.the-infoshop.com/study/dr100334-us-healthc-reform.html The stakes have never been higher or more serious for the pharmaceutical industry - a perfect storm of legislation is moving through Washington, D.C., to address patent reform, healthcare reform, drug importation, authorized generics, biosimilars, and much more. Does the 111th U.S. Congress have the political will to fundamentally change the status quo? One certainty in these uncertain times is that legislation that goes off the table this year is more than likely to resurface next year and the years after that. In this report, we discuss several of the legislative bills of 2009 and the potential impact they could have on the biopharmaceutical industry. en 2009-09-09 Markets and Markets http://www.the-infoshop.com/study/mama99907-autoimm-treat.html The drugs market is estimated to have a revenue of $24.38 billion in 2009, and it is growing with a CAGR of 12.5% from 2009 to 2014. The total services market with therapy and monitoring and drug development as the largest contributor is estimated to be at $9.31 billion in 2009 and it is growing at a CAGR of 14% from 2009 to 2014. Scope of the Report The report provides market overviews and forecasts as well as market drivers and restraints for the global autoimmune treatment market. In addition, it profiles the top forty market players and their respective autoimmune en 2009-09-09 RNCOS E-Services Pvt. Ltd. http://www.the-infoshop.com/study/rnc99934-my-med-tourism.html Malaysia Medical Tourism Outlook 2012 provides thorough analysis of the current market performance and the future outlook of Malaysia' s medical tourism industry. It acknowledges the fact that Malaysia differs vastly from other destinations in terms of cost, infrastructure, human resources, patient perceptions, competencies, and the level of government support. All these factors have been thoroughly studied in the report. In all, the report provides valuable information to clients looking to venture into these markets and helps them to devise strategies while going for an investment/partnership in Malaysia. en Drug Delivery System 2009-09-04 BCC Research http://www.the-infoshop.com/study/bc90900-excipients-pharma.html Powerful forces affect the global excipients industry in 2009, including a crisis in the global supply chain, the demands of Quality by Design (QbD), worries about drug safety, new legislation in the offing, a need for new excipients, exciting ideas for unlocking the industry' s creativity, and new levels of cooperation between major players (e.g., Dow and Colorcon). en 2009-09-04 Business Insights http://www.the-infoshop.com/study/rb99421-ophthalmic-pharma.html The $13.5bn global ophthalmic pharmaceutical market demonstrated low double-digit y-o-y growth in 2008. The emergence of treatment strategies for age-macular degeneration and the subsequent therapeutic and commercial success of Lucentis has led to a substantial rise in overall size of the market while signaling the lucrative and expanding sector within ophthalmology. However, the market faces a patent cliff post 2010 due to patent expiries of class-leading products in anti-glaucoma, ocular anti-allergic and anti-infective/anti-inflammatory therapies. en Pharmaceutical Companies 2009-09-04 Datamonitor http://www.the-infoshop.com/study/dc101024-bristol-myers.html This analysis examines the historical and forecast performance for BMS in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information. en Generic Drugs 2009-09-03 Business Insights http://www.the-infoshop.com/study/rb99422-generics-growth.html The last three years has seen several major shifts in generics company strategies. From 2006 to 2008 a period of high M&A activity was seen as many companies sought to expand geographically and create the scale required to compete with large pharmaceutical companies. Since the global financial crisis the level of deals has declined due to the implications of restricted debt markets and the need to reduce company debt. en Pharmaceutical Companies 2009-09-03 Business Insights http://www.the-infoshop.com/study/rb99423-evolving-pharma.html Pharmaceutical market growth rates have halved inside the past five years, and will remain modest into the next decade. At the same time, new drug approval rates have slowed. With costs continuing to rise, the industry' s margins are already being squeezed, but will come under growing pressure as payers adopt more stringent pharmaceutical cost-containment policies and as patents on a slew of blockbusting brands expire. en Cancer 2009-09-02 La Merie http://www.the-infoshop.com/study/lmer99290-vegf-vegf-r.html The present Competitive Intelligence Report about VEGF and VEGF-R agonists and antagonists provides a competitor evaluation in the field of VEGF and its receptor targeting molecules for treatment of cancer, AMD and for neuroprotection as of September 2009. en Drug Delivery System 2009-09-01 Kalorama Information http://www.the-infoshop.com/study/kl99250-d-delivery-implantable.html With pharmaceutical companies increasingly looking for ways to extend the revenue-earning lifetime of their biggest products, drug delivery has become an important focus of the industry. Kalorama' s Drug Delivery Markets: Implantable / Injectable and Needle-Free Delivery Systems provides detail for business planners on the market for implantable / injectable delivery system markets. en Pharmaceutical Companies 2009-09-01 CurrentPartnering, a division of Wildwood Ventures Limited http://www.the-infoshop.com/study/wild99256-partner-agreement.html The Partnering Agreements in Diagnostics report provides comprehensive understanding and unprecedented access to the diagnostic partnering agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter diagnostic partnering deals. en Cancer 2009-09-01 Asia Market Information & Development Co. http://www.the-infoshop.com/study/amid100198-china-anti-tumor.html China' s demand for Anti-Tumor Drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China' s economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (1998, 2003 and 2008) and long-term forecasts throught 2013 and 2018 are presented. Major producers in China are profiled. en Cancer 2009-09-01 Asia Market Information & Development Co. http://www.the-infoshop.com/study/amid100199-china-colon-cancer.html China' s demand for Colon Cancer Treatment Drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China' s economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (1998, 2003 and 2008) and long-term forecasts throught 2013 and 2018 are presented. Major producers in China are profiled. en Cancer 2009-09-01 Asia Market Information & Development Co. http://www.the-infoshop.com/study/amid100200-china-cervical-cancer.html China' s demand for Cervical Cancer Treatment Drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China' s economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (1998, 2003 and 2008) and long-term forecasts throught 2013 and 2018 are presented. Major producers in China are profiled. en Cancer 2009-09-01 Asia Market Information & Development Co. http://www.the-infoshop.com/study/amid100201-china-brain-cancer.html China' s demand for Brain Cancer Treatment Drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China' s economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. en Cancer 2009-09-01 Asia Market Information & Development Co. http://www.the-infoshop.com/study/amid100203-china-bladder-cancer.html China' s demand for Bladder Cancer Treatment Drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China' s economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (1998, 2003 and 2008) and long-term forecasts throught 2013 and 2018 are presented. Major producers in China are profiled en 2009-09-01 Asia Market Information & Development Co. http://www.the-infoshop.com/study/amid100215-ch-respiratory-drugs.html China' s demand for Respiratory Drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China' s economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. en Neurodegenerative Disease 2009-09-01 Asia Market Information & Development Co. http://www.the-infoshop.com/study/amid100219-china-central-nervous.html China' s demand for Central Nervous System Disorder Drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China' s economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (1998, 2003 and 2008) and long-term forecasts throught 2013 and 2018 are presented. Major producers in China are profiled. en 2009-09-01 Packaged Facts http://www.the-infoshop.com/study/pf100343-count-med-supple.html Sustainability means different things to different people. Asked to identify what the term means to them, consumers most frequently respond the ability to last over time (76%) and the ability to support oneself. Sustainability is also strongly associated with environmental concerns, whereby consumers are being challenged to develop and express an eco-consciousness in their daily habits and purchases. Thus, nearly half of consumers associate sustainability with conserving natural resources and with recycling. en Drug Discovery 2009-09-01 Business Insights http://www.the-infoshop.com/study/rb100890-diabetes-market.html The global diabetes market was worth $27.3bn in 2008 and was led by insulin analogs which captured 45.0% of the market followed by glitazones that captured a share of 22.8%. US is the largest diabetes market globally with sales of $12.9b in 2008 and a market share of 47.6%. en OTC Drug 2009-09-01 Euromonitor International http://www.the-infoshop.com/study/eo101141-healthcare-ecuador.html Euromonitor International' s OTC Healthcare in Ecuador report offers a comprehensive guide to the size and shape of the market at a national level. en OTC Drug 2009-09-01 Euromonitor International http://www.the-infoshop.com/study/eo102715-analgesics-mexico.html Euromonitor International' s Analgesics in Mexico report offers a comprehensive guide to the size and shape of the market at a national level. en OTC Drug 2009-09-01 Euromonitor International http://www.the-infoshop.com/study/eo102716-analgesics-romania.html Euromonitor International' s Analgesics in Romania report offers a comprehensive guide to the size and shape of the market at a national level. en OTC Drug 2009-09-01 Euromonitor International http://www.the-infoshop.com/study/eo102765-remedies-china.html Euromonitor International' s Cough, Cold and Allergy (hay Fever) Remedies in China report offers a comprehensive guide to the size and shape of the market at a national level. en OTC Drug 2009-09-01 Euromonitor International http://www.the-infoshop.com/study/eo102766-remedies-mexico.html Euromonitor International' s Cough, Cold and Allergy (hay Fever) Remedies in Mexico report offers a comprehensive guide to the size and shape of the market at a national level. en OTC Drug 2009-09-01 Euromonitor International http://www.the-infoshop.com/study/eo102767-remedies-romania.html Euromonitor International' s Cough, Cold and Allergy (hay Fever) Remedies in Romania report offers a comprehensive guide to the size and shape of the market at a national level. en OTC Drug 2009-09-01 Euromonitor International http://www.the-infoshop.com/study/eo102774-remedies-china.html Euromonitor International' s Digestive Remedies in China report offers a comprehensive guide to the size and shape of the market at a national level. en OTC Drug 2009-09-01 Euromonitor International http://www.the-infoshop.com/study/eo102775-remedies-mexico.html Euromonitor International' s Digestive Remedies in Mexico report offers a comprehensive guide to the size and shape of the market at a national level. en OTC Drug 2009-09-01 Euromonitor International http://www.the-infoshop.com/study/eo102776-remedies-romania.html Euromonitor International' s Digestive Remedies in Romania report offers a comprehensive guide to the size and shape of the market at a national level. en OTC Drug 2009-09-01 Euromonitor International http://www.the-infoshop.com/study/eo102788-eye-care-china.html Euromonitor International' s Eye Care in China report offers a comprehensive guide to the size and shape of the market at a national level. en OTC Drug 2009-09-01 Euromonitor International http://www.the-infoshop.com/study/eo102789-eye-care-mexico.html Euromonitor International' s Eye Care in Mexico report offers a comprehensive guide to the size and shape of the market at a national level. en OTC Drug 2009-09-01 Euromonitor International http://www.the-infoshop.com/study/eo102790-eye-care-romania.html Euromonitor International' s Eye Care in Romania report offers a comprehensive guide to the size and shape of the market at a national level. en OTC Drug 2009-09-01 Euromonitor International http://www.the-infoshop.com/study/eo102870-smoking-mexico.html Euromonitor International' s NRT Smoking Cessation Aids in Mexico report offers a comprehensive guide to the size and shape of the market at a national level. en OTC Drug 2009-09-01 Euromonitor International http://www.the-infoshop.com/study/eo102871-smoking-romania.html Euromonitor International' s NRT Smoking Cessation Aids in Romania report offers a comprehensive guide to the size and shape of the market at a national level. en OTC Drug 2009-09-01 Euromonitor International http://www.the-infoshop.com/study/eo102876-healthcare-ecuador.html Euromonitor International' s OTC Healthcare - Ecuador report offers a comprehensive guide to the size and shape of the market at a national level. en OTC Drug 2009-09-01 Euromonitor International http://www.the-infoshop.com/study/eo102986-treatments-china.html Euromonitor International' s Wound Treatments in China report offers a comprehensive guide to the size and shape of the market at a national level. en OTC Drug 2009-09-01 Euromonitor International http://www.the-infoshop.com/study/eo102987-treatments-mexico.html Euromonitor International' s Wound Treatments in Mexico report offers a comprehensive guide to the size and shape of the market at a national level. en OTC Drug 2009-09-01 Euromonitor International http://www.the-infoshop.com/study/eo102988-treatments-romania.html Euromonitor International' s Wound Treatments in Romania report offers a comprehensive guide to the size and shape of the market at a national level. en Pharmaceutical Companies 2009-08-31 Espicom Business Intelligence http://www.the-infoshop.com/study/es13879-pharmaceutical.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. en Pharmaceutical Companies 2009-08-31 Espicom Business Intelligence http://www.the-infoshop.com/study/es15737-gr-pharma.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. en Pharmaceutical Companies 2009-08-31 Espicom Business Intelligence http://www.the-infoshop.com/study/es16660-sanofi-aventis.html This report provides a full review of the company's activities together with sales forecasts for key products to 2010. en Pharmaceutical Companies 2009-08-31 Espicom Business Intelligence http://www.the-infoshop.com/study/es17837-pharma-peru.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. en Pharmaceutical Companies 2009-08-31 Espicom Business Intelligence http://www.the-infoshop.com/study/es17838-tr-pharma.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. en Pharmaceutical Companies 2009-08-31 Espicom Business Intelligence http://www.the-infoshop.com/study/es19785_abbott.html This new strategic analysis report Abbott Laboratories: Performance, Products, Pipeline and Potential, provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. The report is updated on a quarterly basis. Buyers of the web edition receive quarterly reports for a year. Buyers of the print/pdf editions receive the latest version. All formats are the same price. en Pharmaceutical Companies 2009-08-31 Espicom Business Intelligence http://www.the-infoshop.com/study/es20785_austria_pharmaceutical.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. en Pharmaceutical Companies 2009-08-31 Espicom Business Intelligence http://www.the-infoshop.com/study/es20875_johnson_johnson.html Headquartered in New Jersey, Johnson & Johnson is a comprehensive manufacturer of healthcare products and related services. It has over 200 operating companies in 57 countries around the world, employing over 110,000 people and selling products in more than 175 countries. en Pharmaceutical Companies 2009-08-31 Espicom Business Intelligence http://www.the-infoshop.com/study/es42296-kyowa-hakko.html This report provides a full review of the company's activities together with sales forecasts for key products to 2010. en Pharmaceutical Companies 2009-08-31 Espicom Business Intelligence http://www.the-infoshop.com/study/es66458-shire.html Shire is a leading specialty pharmaceutical company traditionally focused on the treatment of attention deficit hyperactivity disorder (ADHD) and gastrointestinal disorders. en Regulation 2009-08-31 Espicom Business Intelligence http://www.the-infoshop.com/study/es97246-pharma-korea.html Espicom' s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. en Infection Disease 2009-08-31 ResearchInChina http://www.the-infoshop.com/study/rinc97656-cn-vaccine.html Based on authoritative statistics, this report makes in-depth analysis on China vaccine industry development, vaccine market, vaccine import & export, key vaccine producers, and also forecasts the development trend of China' s vaccine industry in 2009. Vaccines involved in this report are Flu Vaccine, HBV Vaccine, Cerebrospinal Meningitis Vaccine, HIV vaccine, A/HINI vaccine as well as animal vaccines. en Neurodegenerative Disease 2009-08-31 Decision Resources, Inc. http://www.the-infoshop.com/study/dr99260-pricing-neurology-drugs.html Neurological disorders will impose a growing social and fi nancial burden on the major pharmaceutical markets as the elderly population in these countries increases steadily. Governments and other payers recognize the pressing need to tackle these diseases, but they also have to control the relentless growth of healthcare expenditures. en Generic Drugs 2009-08-31 Datamonitor http://www.the-infoshop.com/study/dc99295-generic-strategies.html The emerging markets are luring a growing number of pharma companies looking to compensate for the diminishing revenues in developed markets. Latin America and Central and Eastern Europe (CEE) are showing strong growth rates, proving to be lucrative targets for firms aiming to expand their foothold, initially as a generics player, but also providing a foundation for subsequent brand penetration. en Vaccines 2009-08-31 BCC Research http://www.the-infoshop.com/study/bc99390-influenza.html Provides a thorough evaluation of the market for influenza vaccines, therapeutics, and diagnostics Offers a global analysis, with emphasis on U.S. data, and a five-year forecast period through 2014 Identifies markets in the segments of vaccines/therapeutics and diagnostics. en Pharmaceutical Companies 2009-08-31 Business Insights http://www.the-infoshop.com/study/rb99393-cro-market.html The report analyzes the overarching trends in the industry; examines which regions are set to see growth in CRO activity; evaluates the leading CROs; and outlines the future of the industry. The report provides insight into conditions into seven emerging regions including China, India and Latin America. It highlights the evolving business and relationship models between CROs and sponsor companies and enables optimal outsourcing strategy. en OTC Drug 2009-08-31 Mintel International Group Ltd, http://www.the-infoshop.com/study/mt99584-otc-products.html Alongside a drop in the number of GP appointments for children and move towards pharmacist-led medication, the rising child population will contribute to the ’20 million growth of the market to 2014. en Cancer 2009-08-27 Decision Resources, Inc. http://www.the-infoshop.com/study/dr98893-chronic-myelogenous.html Chronic myelogenous leukemia (CML) is a rare blood cancer; nonetheless, CML treatments garner substantial revenues. Despite recent advances in the treatment of this disease (most notably, targeted therapeutics such as Novartis' s Gleevec/Glivec [imatinib]), signifi cant unmet needs remain because certain segments of the CML patient population are intolerant of or become resistant to existing therapies. en Regulation 2009-08-27 Espicom Business Intelligence http://www.the-infoshop.com/study/es98944-world-healthc-org.html Barack Obama' s plans for healthcare reform in the US have generated a great deal of controversy, with opponents appalled at what they see as an increasing tax burden and over involvement of the state. In contrast, the UK' s NHS provides a comprehensive state-funded health service for everyone at the point of need. Despite detractors, the UK model is widely admired and vigorously defended even though such a scheme is anathema to the antireformists in the USA. Are these polarised opinions based on misinformation or a genuine philosophical divergence, and how does the rest of the world approach organised healthcare? en 2009-08-27 Datamonitor http://www.the-infoshop.com/study/dc99200-multi-marketing.html The future of Pharma marketing lies in using new marketing channels such as social media intertwined with traditional marketing practices to create a multi-channel marketing mix. en Regulation 2009-08-27 Business Monitor International http://www.the-infoshop.com/study/bmi99431-algeria-pharmaceuticals.html In BMI's Q409 Business Environment Rankings matrix for the 17 key countries of the Middle East and Africa (MEA) region, Algeria remains in a lowly 14th position. en Regulation 2009-08-27 Business Monitor International http://www.the-infoshop.com/study/bmi99485-oman-pharmaceuticals.html In the Q409 BMI's Business Environment Ranking (BER) matrix for Middle East and Africa (MEA), Oman is placed seventh, having improved its position by three places in relation to the previous quarter. en Regulation 2009-08-27 Business Monitor International http://www.the-infoshop.com/study/bmi99501-serbia-pharmaceuticals.html In the BMI's Q409 Business Environment Rating (BER) matrix, Serbia continued to improve its placement, and is now found in 9th position, out of the 20 key markets surveyed in the Emerging Europe region. en Regulation 2009-08-27 Business Monitor International http://www.the-infoshop.com/study/bmi99523-pharmaceuticals.html Recent months have shown that Uzbekistan's economy remains resilient if not immune to the global financial crisis. en Regulation 2009-08-27 Visiongain http://www.the-infoshop.com/study/kt100723-chinese-pharma.html This report - Chinese Pharmaceutical Market Outlook 2009-2024 - analyses prospects for the pharma market and industry sector in China. This new study discusses market drivers and restraints such as production capacity, intellectual property rights and the high, fast-growing healthcare demands in China. Importantly, we provide detailed sales forecasting at the core of the analyses. en Regulation 2009-08-26 Frost & Sullivan http://www.the-infoshop.com/study/fs98806-zw-healthcare.html This research service presents an in-depth analysis of the Zambian healthcare industry. It provides a general insight into processes of regulations, medical insurance, healthcare procurement and financing. en Regulation 2009-08-26 Business Monitor International http://www.the-infoshop.com/study/bmi99435-argentina-pharmaceuticals.html BMI calculates Argentina's pharmaceutical expenditure to have been ARS11.56bn (US$3.73bn) in 2008. en Regulation 2009-08-26 Business Monitor International http://www.the-infoshop.com/study/bmi99456-france-pharmaceuticals.html In BMI's Business Environment Rankings (BER) for Q409, France remains ranked 3rd out of the 9 Western European markets surveyed. en Regulation 2009-08-26 Business Monitor International http://www.the-infoshop.com/study/bmi99460-hungary-pharmaceuticals.html In BMI's Business Environment Ratings (BER) for Q409, Hungary remains ranked 11th, out of the 20 major markets within Central and Eastern Europe (CEE), its position having worsened in recent months. en Regulation 2009-08-26 Business Monitor International http://www.the-infoshop.com/study/bmi99467-indonesia-pharmaceuticals.html In BMI's Business Environment Rating matrix for Q409, Indonesia once again occupies 12th position, out of the 15 regional markets surveyed in the Asia Pacific region. en Regulation 2009-08-26 Business Monitor International http://www.the-infoshop.com/study/bmi99481-morocco-pharmaceuticals.html BMI expects the drug market in Morocco to increase in value from US$1.38bn in 2008 to US$1.88bn in 2013, representing a compound annual growth rate (CAGR) of 5.5% in US dollar terms. en Regulation 2009-08-26 Business Monitor International http://www.the-infoshop.com/study/bmi99509-pharmaceuticals.html Slovenia is ranked in 9th position in BMI's Business Environment Ratings for Central and Eastern Europe (CEE) in Q409, highlighting it as a reasonably attractive investment opportunity for drugmakers. en Regulation 2009-08-26 Business Monitor International http://www.the-infoshop.com/study/bmi99516-turkey-pharmaceuticals.html In BMI's regional Pharmaceutical & Healthcare Business Environment Rankings (BER) for Q409, Turkey's score dropped relative to the previous two quarters. en Generic Drugs 2009-08-26 Visiongain http://www.the-infoshop.com/study/kt100722-world-generics.html The generic pharmaceuticals sector has been expanding strongly in recent years as the need for cheaper medicines worldwide has increased. The next five years from 2009 will see more leading drugs going off patent, thus increasing opportunities for generics producers. en Drug Discovery 2009-08-25 BioSeeker Group AB http://www.the-infoshop.com/study/bg99264-lung-cancer.html This report includes defined and up to date development strategies for 283 lung cancer therapeutic drugs (>317 projects) within the portfolio of 167 investigators, from Ceased to Marketed. In total the report assesses three different sub-indications of lung cancer (Non-Small Cell Lung Cancer, Small Cell Lung Cancer and Lung Cancer (general). en Generic Drugs 2009-08-21 Espicom Business Intelligence http://www.the-infoshop.com/study/es98613-generic-drug.html While controlled-release products have traditionally been developed towards the patent-expiry, companies are now beginning to look at controlled-release delivery earlier in the product life-cycle and, in some cases, are launching immediate- and controlled-release versions of new drugs to address the differing needs of patients. A number of significant controlled-release drugs - some of them blockbusters - will lose patent protection in the medium term. This has led to increased interest from a range of companies vying for a share of the controlled-release generics market. en Neurodegenerative Disease 2009-08-20 Decision Resources, Inc. http://www.the-infoshop.com/study/dr98548-neurological-disease.html How can early-stage R&D efforts be positioned to tap the remaining opportunity in the neurology drug market? Although brimming with potential, neurology drug development is also rife with unique challenges that many companies and agents have been unable to overcome, as witnessed by the failures of agents initially deemed highly promising. en 2009-08-19 Frost & Sullivan http://www.the-infoshop.com/study/fs98482-eu-lifesty-disorder.html This research service deals with market drivers, restraints, market trends, competitive structure, revenues and market attractiveness analysis of the European lifestyle disorders therapeutics market. en OTC Drug 2009-08-19 PMR http://www.the-infoshop.com/study/pmr98567-otc-market-c-e-euro.html OTC market in Central and Eastern Europe 2009, Comparative analysis and development forecasts 2009-2011 supplies all the latest data, analysis and forecasts for the OTC market in CEE, with special emphasis on the robust markets of Russia, Poland, Ukraine, the Czech Republic, Romania, Bulgaria, Hungary, Slovakia, Slovenia and Croatia. en Mental Disease 2009-08-18 Decision Resources, Inc. http://www.the-infoshop.com/study/dr98425-autism-spectrum-disorder.html An increase in public funding for research and a heightened interest among drug developers suggest that a breakthrough in autism spectrum disorder (ASD) treatment may be imminent. en 2009-08-17 Datamonitor http://www.the-infoshop.com/study/dc99560-antihypertensives.html Following the patent expiries of angiotensin-II receptor blockers Datamonitor expects antihypertensives sales in the seven major markets to record sales of $29.5 billion in 2018, a drop of over $6 billion compared to 2008. en Drug Discovery 2009-08-15 La Merie http://www.the-infoshop.com/study/lmer98659-hepatitis-c-thera.html The present Competitive Intelligence Report about Targeted Therapy of Hepatitis C provides a competitor evaluation in the field of specifically targeted antiviral therapeutics for hepatitis C (STAT-C) as of August 2009. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. en OTC Drug 2009-08-15 Euromonitor International http://www.the-infoshop.com/study/eo100982-sleeping-chile.html This report presents Calming And Sleeping Products in Chile. en OTC Drug 2009-08-15 Euromonitor International http://www.the-infoshop.com/study/eo101014-contraception-chile.html This report presents Emergency Contraception in Chile. en OTC Drug 2009-08-15 Euromonitor International http://www.the-infoshop.com/study/eo101040-otc-chile.html The OTC healthcare market in 2008 recorded growth that was similar to the average for the review period. en Neurodegenerative Disease 2009-08-14 Datamonitor http://www.the-infoshop.com/study/dc98356-alzheimers-disease.html Driven by the launch of disease modifying treatments and an expanding patient population, the Alzheimer' s disease market will more than double over the next 10 years. Late-stage pipeline products such as Pfizer/Medivation' s Dimebon (latrepirdine) and Johnson & Johnson/Wyeth' s bapineuzumab hold blockbuster potential. However, the risk of clinical trial failure remains high in this indication. en Regulation 2009-08-14 Business Monitor International http://www.the-infoshop.com/study/bmi99304-pharmaceuticals.html Of the 15 key markets surveyed in BMI's Pharmaceuticals & Healthcare Business Environment Rankings, Bangladesh is placed in 14th position, and can be found above Vietnam, the latter being judged the least attractive proposition for investment. en Regulation 2009-08-14 Business Monitor International http://www.the-infoshop.com/study/bmi99345-pharmaceuticals.html Our forecasts reveal a modest compound annual growth rate (CAGR) of around 9.7% in US dollar terms for Mexico's total drug market value, which is forecast to reach US$15.7bn by 2013. en Regulation 2009-08-14 Business Monitor International http://www.the-infoshop.com/study/bmi99349-pharmaceuticals.html In BMI's Business Environment Rankings (BER) matrix for Q409, Pakistan slightly improved its position, now ranking joint 13th out of the 15 markets assessed in the Asia Pacific region. en Pharmaceutical Companies 2009-08-13 La Merie http://www.the-infoshop.com/study/lmer98543-target-pipeline.html The Coagulation Factors 2009: Target Pipeline and Corporate Benchmark Analysis report is the most complete and up-to-date evaluation and assessment of the recombinant and plasma-derived coagulation factor pipelines. The authors analyze and assess the target pipeline for each of the coagulation factors used for systemic and topical administration. Companies active in the therapeutic coagulation business are evaluated and the strengths, weaknesses, opportunities and threats (SWOT) in their R&D pipeline benchmarked in the respective peer group. Technologies used for creation of next generation coagulation factors are discussed and assessed. The report identifies strategies to overcome weaknesses in the portfolio and suggests development strategies en Diabetes 2009-08-12 Mintel International Group Ltd, http://www.the-infoshop.com/study/mt97693-adult-obesity.html More than 150 million adults in the US are overweight or obese, and this affects businesses in diverse categories, including food service, supermarkets, airlines, healthcare, and weight loss. en OTC Drug 2009-08-12 Business Insights http://www.the-infoshop.com/study/rb97734-npd-preventive.html 1This report examines which preventive health trends, and which regions, consumer groups, and product categories have shown growth up to 2008, and evaluates which are best placed for growth over the next five years. en Cancer 2009-08-12 Business Insights http://www.the-infoshop.com/study/rb97737-volving-strategies.html 1The emergence of a new wave of oncology products has been one of the most dramatic trends in the pharmaceutical market over the last decade. Both large and small companies are making unprecedented investments in oncology R&D, in an effort to emulate the success of new targeted therapies such as Herceptin, Avastin, Glivec, Nexavar and Erbitux. en Pharmaceutical Companies 2009-08-12 Business Insights http://www.the-infoshop.com/study/rb97738-pharma-force-effect.html 1The social, demographic and economic context in which the pharmaceutical industry operates is changing dramatically, with huge implications for the industry as a whole. All these challenges have major ramifications for the way in which pharmaceutical companies market and sell the medicines they develop. With these challenges comes pressure to gain efficiencies in all facets of the business, but perhaps no aspect of pharma operations is under as much scrutiny as the sales and marketing function. en Regulation 2009-08-12 Business Monitor International http://www.the-infoshop.com/study/bmi99300-pharmaceuticals.html In 2008, Australia's pharmaceutical market was worth US$6.93bn, it is forecast to reach US$7.28bn in 2009 and rise to over US$10bn in 2013, which represents a compound annual growth rate (CAGR) of 7.72. en Regulation 2009-08-12 Business Monitor International http://www.the-infoshop.com/study/bmi99315-croatia-pharmaceuticals.html In the BMI's Q409 Pharmaceuticals & Healthcare Business Environment Rankings (BER) for Central and Eastern Europe (CEE), Croatia is once again 10th of the 20 regional markets surveyed. en Regulation 2009-08-12 Business Monitor International http://www.the-infoshop.com/study/bmi99337-pharmaceuticals.html BMI's new Pharmaceutical & Healthcare Report for Q409 forecasts that the value of the Jordanian drug market will increase from around JOD263mn (US$370mn) in 2008 to JOD369mn (US$519mn) by 2013. en Regulation 2009-08-12 Business Monitor International http://www.the-infoshop.com/study/bmi99339-pharmaceuticals.html BMI calculates Kenya's pharmaceutical expenditure to have been KES15.85bn (US$229mn) in 2008. en Regulation 2009-08-12 Business Monitor International http://www.the-infoshop.com/study/bmi99346-pharmaceuticals.html For BMI's Q409 Nigeria Pharmaceutical and Healthcare report, we expect total drug market spending in the country to rise from US$633mn in 2008 to US$695mn by 2013, representing a compound annual growth rate (CAGR) of 1.59% in US dollar terms and 3.24% in local currency. en Regulation 2009-08-12 Business Monitor International http://www.the-infoshop.com/study/bmi99352-pharmaceuticals.html the third-largest market in Central and Eastern Europe (CEE), on face value Poland remains one of the biggest opportunities for multinational pharmaceutical companies. en Regulation 2009-08-12 Business Monitor International http://www.the-infoshop.com/study/bmi99372-zimbabwe-pharmaceuticals.html There are some green shoots of hope appearing in the wreckage of Zimbabwe's healthcare sector, as a number of foreign companies are considering re-investing in the country. en 2009-08-11 Cutting Edge Information http://www.the-infoshop.com/study/cei97339-patient-communication.html What does an effective patient communications program look like? In today' s information-hungry environment, it takes more than a company website to motivate patients. Although developing a superior program involves vetting a dizzying number of options, if your brand succeeds, the benefits are palpable: earn customers' trust, win higher brand awareness and loyalty, improve patient adherence, and generate sales. en OTC Drug 2009-08-10 Datamonitor http://www.the-infoshop.com/study/dc99979-otc-pharma-bric.html This report contains easily comparable data on market value, volume, segmentation and market share for the BRIC countries OTC Pharmaceuticals market, plus full fiveyear market forecasts. It examines future problems, innovations and potential growth areas within the market. en OTC Drug 2009-08-10 Datamonitor http://www.the-infoshop.com/study/dc99981-otc-pharma-global.html The Group of Eight (G8) is a forum for the governments of eight nations of the northern hemisphere: Canada, France, Germany, Italy, Japan, Russia, UK and the US. Together, the G8 countries represent about 65% of Gross World Product. en OTC Drug 2009-08-10 Datamonitor http://www.the-infoshop.com/study/dc99987-otc-pharma.html The North American Free Trade Agreement (NAFTA) is a trilateral trade bloc in North America (the US, Canada, and Mexico). This report contains easily comparable data on market value, volume, segmentation and market share across NAFTA bloc countries in the OTC Pharmaceuticals market, plus full five-year market forecasts. It examines future problems, innovations and potential growth areas within the market. en OTC Drug 2009-08-10 Datamonitor http://www.the-infoshop.com/study/dc100002-otc-pharma-scandinavia.html Scandinavia is a historical and geographical region in Northern Europe that includes Norway, Sweden, and Denmark. This report contains easily comparable data on market value, volume, segmentation and market share for the OTC Pharmaceuticals industry in the Scandinavian countries, plus full five-year market forecasts. It examines future problems, innovations and potential growth areas within the market. en 2009-08-10 Datamonitor http://www.the-infoshop.com/study/dc100004-pharma-scandinavia.html Scandinavia is a historical and geographical region in Northern Europe that includes Norway, Sweden, and Denmark. This report contains easily comparable data on market value, volume, segmentation and market share for the Pharmaceuticals industry in the Scandinavian countries, plus full five-year market forecasts. It examines future problems, innovations and potential growth areas within the market. en Diabetes 2009-08-09 RNCOS E-Services Pvt. Ltd. http://www.the-infoshop.com/study/rnc98349-insulin-deli-sys.html The report provides extensive information and rational analysis on the global insulin market as well as insulin delivery methods. Thus, it provides valuable information to pharmaceutical and biotech companies and investors looking to enter this market. Analysis and statistics regarding market size, growth, share, regulatory environment and trends in technology development have been thoroughly analyzed in the report to provide clients a comprehensive overview of the market. en 2009-08-09 RNCOS E-Services Pvt. Ltd. http://www.the-infoshop.com/study/rnc98392-sa-healthcare.html Our new research report Saudi Arabian Healthcare Market Forecast to 2012 says that the healthcare sector in Saudi Arabia is expected to enjoy a double-digit growth in future. The pharmaceutical market and medical device market in Saudi Arabia are forecasted to grow at a CAGR of around 12% and 7% respectively. Currently, the market is characterized by huge private investments and this trend is likely to continue in near future also. en Generic Drugs 2009-08-09 RNCOS E-Services Pvt. Ltd. http://www.the-infoshop.com/study/rnc98394-generic-drug-canada.html Canada represents one of the largest markets for pharmaceuticals in the world, with a huge potential for generics. In 2008, generics accounted for more than 51% prescriptions and around 23% sales of the total pharmaceutical market. en Regulation 2009-08-06 Decision Resources, Inc. http://www.the-infoshop.com/study/dr97247-market-access-pricing.html The second quarter of 2009 saw steady progress toward healthcare reform in the United States and action in several of the world' s other major pharmaceutical markets to curb pharmaceutical expenditures. en Infection Disease 2009-08-06 Datamonitor http://www.the-infoshop.com/study/dc97861-influenza-vaccine.html Fuelled by the pandemic flu threat, the influenza market has expanded rapidly in recent years. This growing commercial opportunity has encouraged companies to develop new technologies and increase manufacturing capacity for influenza vaccines and antivirals. The H1N1 pandemic will stimulate further growth, but also confronts industry and public health stakeholders with new challenges. en Infection Disease 2009-08-06 Datamonitor http://www.the-infoshop.com/study/dc99578-influenza-vaccines.html Fuelled by the pandemic flu threat, the influenza market has expanded rapidly in recent years. This growing commercial opportunity has encouraged companies to develop new technologies and increase manufacturing capacity for influenza vaccines and antivirals. en 2009-08-05 BCC Research http://www.the-infoshop.com/study/bc96391-pain-management.html The global market for pain management pharmaceuticals and devices amounted to $19.1 billion in 2008 and is expected to increase to $32.8 billion in 2013. The compound annual growth rate (CAGR) for the 5-year period is projected at 11.5%. en Drug Delivery System 2009-08-05 BCC Research http://www.the-infoshop.com/study/bc96392-advanced-drug.html This study encompasses the major types of drug delivery systems used in the health industry. BCC analyzes each technology and looks at the manufacturers, their new products, sales estimates, market projections, and some market share information. BCC analyzes the industry on a worldwide basis. en 2009-08-05 Global Markets Direct http://www.the-infoshop.com/study/labd98126-ingredients.html This report will provide an analysis of the Active Pharmaceutical Ingredients market in key countries of North America region. en 2009-08-03 MarketData Enterprises, Inc. http://www.the-infoshop.com/study/md96327-us-fertility-clinic.html This unique new study by Marketdata examines the nature/evolution of the business, national receipts/growth from 1988 to 2013 forecast, extensive infertile customer demographics, key industry trends, industry regulation, pricing, industry consolidation, insurance coverage, ethical issues and calls for reform, effects of the recession, and more. The study presents the findings of Marketdata' s mail/phone survey of fertility clinic managers, with average costs and number of specific diagnostic procedures. Contains results of the latest (2006 & 2007) CDC ART surveys, with IVF success rates, plus a name/address directory of 400+ fertility clinics, as well as European ART cycles survey data. Examines the sperm banks, egg donors, and fertility drugs markets, and surrogacy programs. en Neurodegenerative Disease 2009-08-03 Decision Resources, Inc. http://www.the-infoshop.com/study/dr97066-neurology-pipeli.html Mega-blockbuster status would be quick and sure for any safe, effective agent that prevents the death and damage of neurons associated with neurodegenerative diseases. The potential of such a neuroprotectant is one of the motivations for the 188 companies currently involved in the development of 263 neurological pipeline agents, despite the plethora of marketed agents for these diseases and disorders. Meanwhile, less-debilitating neurological disorders that nonetheless affect patients' quality of life (e.g., migraine, insomnia) also face signifi cant unmet needs. Today' s pipeline of new molecular entities (NMEs) and reformulations holds a range of agents with potential to improve treatment and infl uence market dynamics, as well as drive market growth through 2015.